Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Study Shows Direct Link Between H Pylori and Gastric Cancer

October 1, 1999
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

ORLANDO-Researchers from Kure, Japan, reported on the first prospective study to show a direct connection between infection with Helicobacter pylori and the onset of gastric cancer. Their work, presented at the Digestive Disease Week meeting, builds upon epidemiologic research done in the early 1990s that strongly suggested such an association.

ORLANDO—Researchers from Kure, Japan, reported on the first prospective study to show a direct connection between infection with Helicobacter pylori and the onset of gastric cancer. Their work, presented at the Digestive Disease Week meeting, builds upon epidemiologic research done in the early 1990s that strongly suggested such an association.

The study involved 1,166 patients with gastric disease who were tested for H pylori infection. The researchers took pains to ensure the accuracy of all negative readings. Each patient underwent three tests for the presence of H pylori: histology, a rapid urease test, and a serologic test.

“If all three tests were negative, we knew the patient was negative for H pylori,” Naami Uemara, MD, said in an interview. “Each test yields a false negative about 20% of the time. With three tests in agreement, you eliminate false negatives.” Dr. Uemara, chief of gastroenterology at Kure Kyosai Hospital, led the research team.

Of the total group, 246 were negative for H pylori while 920 were positive. Patients who tested positive for H pylori had the following diagnoses: chronic gastritis, (382 patients), active gastric ulcer (186), active duodenal ulcer (180), gastric polyp (172).

All patients underwent endoscopy at least once every 2 years. Therapy to eradicate H pylori was not employed in any of the patients. The follow-up period ranged from 5 to 8.5 years, and averaged 7 years.

Among patients free of H pylori, follow up endoscopy has revealed no cases of gastric cancer. In contrast, at the time of this analysis, the researchers had discovered gastric cancer in 17 of the 920 patients infected with H pylori (P < .05).

Histology revealed that 12 of the gastric cancers were of the intestinal type, and 5 were of the diffuse type. “This led us to conclude that, in humans, H pylori-associated gastritis causes the onset of both types of gastric cancer,” Dr. Uemara commented.

Articles in this issue

Henderson Offers ‘Take-Home Messages’ From Endocrine Studies
Sustained-Release Cytarabine for Lymphomatous Meningitis
Scintimammography Detects Tumors in Dense Breast Tissue
Autologous Vaccine as Adjuvant Therapy for Melanoma
Breast Cancer Screening in Women 40 to 49
Limited Surgery Better in Colon Cancer With Diffuse Liver Mets
Risk Factors for Local Recurrence After Breast-Conserving Therapy
New Brain Imaging Technique Cuts MR Scan Time in Half
NCI Is Testing Thalidomide to Prevent Colorectal Cancer Recurrence
Penn Cancer Center Sponsors Exhibit of Cancer Patients’ Art
Geffen Cancer Center Uses Western Medicine, Eastern Philosophy
Fatigue More Severe Than Anticipated in Palliative Medicine
Lower Levels of IGF Binding Protein Seen in High-Risk Black Men
Randomized Trials Needed to Settle Prostate Cancer Controversies
Tamoxifen Plus Goserelin as Adjuvant Therapy

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
2 experts in this video
2 experts in this video
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Related Content

Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma

Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma

Ariana Pelosci
June 14th 2025
Article

Results of the PREDATOR-MRD trial found that daratumumab could help predict MRD response for patients with multiple myeloma.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Dasatinib Misses Survival End Points in Core-Binding Factor AML

Dasatinib Misses Survival End Points in Core-Binding Factor AML

Ariana Pelosci
June 14th 2025
Article

Compared with standard therapy, dasatinib did not improve efficacy for patients with core-binding factor AML.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


Biomarker analyses indicate the predictive potential of a 15-protein signature related to the efficacy of serplulimab plus chemotherapy in ES-SCLC.

Serplulimab Yields Sustained OS/PFS Benefits in Extensive-Stage SCLC

Russ Conroy
June 14th 2025
Article

Biomarker analyses indicate the predictive potential of a 15-protein signature related to the efficacy of serplulimab plus chemotherapy in ES-SCLC.


JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL

JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL

Tim Cortese
June 13th 2025
Article

JNJ’4496 at 75 M CAR T cells elicited an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

Related Content

Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma

Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma

Ariana Pelosci
June 14th 2025
Article

Results of the PREDATOR-MRD trial found that daratumumab could help predict MRD response for patients with multiple myeloma.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Dasatinib Misses Survival End Points in Core-Binding Factor AML

Dasatinib Misses Survival End Points in Core-Binding Factor AML

Ariana Pelosci
June 14th 2025
Article

Compared with standard therapy, dasatinib did not improve efficacy for patients with core-binding factor AML.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


Biomarker analyses indicate the predictive potential of a 15-protein signature related to the efficacy of serplulimab plus chemotherapy in ES-SCLC.

Serplulimab Yields Sustained OS/PFS Benefits in Extensive-Stage SCLC

Russ Conroy
June 14th 2025
Article

Biomarker analyses indicate the predictive potential of a 15-protein signature related to the efficacy of serplulimab plus chemotherapy in ES-SCLC.


JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL

JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL

Tim Cortese
June 13th 2025
Article

JNJ’4496 at 75 M CAR T cells elicited an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.